チカルシリン・クラブラン酸

チカルシリン・クラブラン酸 化学特性,用途語,生産方法

• 効能

  抗生物質

• 抗菌性

  Activity is that of ticarcillin , the role of the inhibitor being to restore the activity against β-lactamase-producing strains that would otherwise hydrolyze the drug.

• 薬物動態学

  C_max 3 g ticarcillin + 100 mg: 330 mg/L end: 8 mg/L end
  clavulanate intravenous: infusion: infusion
  infusion (30 min)
  Plasma half-life: 1.1 h 1.1 h
  Plasma protein binding: 45% 25%
  The pharmacokinetics of the two agents are mutually unaffected by co-administration. Ticarcillin can be detected in tissues and interstitial fluid following parenteral administration. Penetration into bile, peritoneal fluid and pleural fluid has been demonstrated. Concentrations in blister fluid were significantly lower than those in serum.
  Around 60–70% of ticarcillin and 35–45% of clavulanic acid are excreted unchanged in urine during the first 6 h after administration of a single dose of the mixture.

• 臨床応用

  Septicemia, including bacteremia
  Lower respiratory infections
  Bone and joint infections
  Skin and skin structure infections
  Urinary tract infections (complicated and uncomplicated)
  Gynecological infections, endometritis
  Intra-abdominal infections, peritonitis
  Its main use is in infections in which Ps. aeruginosa is suspected or proven.

• 副作用

  Adverse reactions associated with ticarcillin occur . As with co-amoxiclav, there is a risk of cholestatic jaundice . Pseudomembranous colitis has been reported.

チカルシリン・クラブラン酸 生産企業

Global(34)Suppliers

86482-18-0, チカルシリン・クラブラン酸 キーワード